Lv61
1720 积分 2025-05-20 加入
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-hodgkin lymphoma
28天前
已完结
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-hodgkin lymphoma
1个月前
已完结
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
1个月前
已完结
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
1个月前
已完结
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
2个月前
已完结
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
2个月前
已完结
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms
2个月前
已完结
Marginal-Zone Lymphomas
3个月前
已完结
Marginal-Zone Lymphomas
3个月前
已完结
Oxaliplatin-related side effects: Characteristics and management
3个月前
已关闭
皖公网安备34019202002308
